Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Phase 3 Recruiting 1000 enrolled Philip Spinella Biomedical Advanced Research and Development Authority · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.

Timeline

Start: 2024-11-01
Primary completion: 2028-06-01
Completion: 2028-10-01

Publications

Petersen EM, Fisher AD, April MD, Yazer MH, Braverman MA, Borgman MA, Schauer SG. The effect of the proportion of low-titer O whole blood for resuscitation in pediatric trauma patients on 6-, 12- and 24-hour survival. J Trauma Acute Care Surg. 2025 Apr 1;98(4):587-592. doi: 10.1097/TA.0000000000004564. Epub 2025 Feb 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Low Titer Group O Whole Blood	Unknown	8 unknown	—
Subject	Plasma	Other / unclassified	—	—
Subject	RBCs	Unknown	—	—
Subject	Tranexamic Acid	Small molecule	25 mg/kg	Intravenous
Subject	platelet units	Unknown	—	—

Indications

No indication recorded.